ADVA
13.4.2021 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has successfully demonstrated interoperability between its next-generation FSP 3000 DCI open line system (OLS) and QSFP-DD 400ZR modules from Acacia Communications and Inphi Corporation. Conducted over a 120km amplified link, the tests show a clear path to commercial deployments of a complete solution with all the benefits of open, programmable networking. The trial featured 400Gbit/s WDM transport using low-power 400ZR pluggable QSFP-DD transceivers from Acacia and Inphi with ADVA’s FSP 3000 DCI OLS . It was carried out under real-world conditions with 400Gbit/s channels placed next to the test channels as well as a fully loaded spectrum. To validate three-way line-side interoperability, 400ZR was transmitted from Acacia to Inphi and vice versa. Test results showed that this multi-vendor ecosystem exceeds all OIF 400ZR Implementation Agreement performance metrics. Large-scale DCI network operators now have an easy and cost-effective route to a dynamic, future-proof and open environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005107/en/
“Today, we’re showing a direct route to open DCI networking using 400ZR. By proving the next-level interoperability of our platform with Acacia and Inphi’s optical interconnect technology, we’re empowering network operators to effortlessly harness the benefits of both 400ZR and open infrastructure. This will be key to reducing cost and complexity in the new breed of high-bandwidth DCI networks,” said Steve Penticost, VP, global business development, ADVA. “Others may talk about openness, but our track record with multi-vendor innovation speaks for itself. With thousands of our DCI OLS deployed, we’re already giving huge numbers of networks across the planet the freedom to select any components and leverage different innovation cycles.”
The ADVA FSP 3000 DCI OLS is the market’s most comprehensive OLS platform. Its open and modular design removes all restrictions of traditional closed systems and puts DCI network operators in complete control. With ADVA’s unrivalled experience of managing APIs in DCI architectures, the platform extends SDN to the transport layer. Designed to interoperate with all standards-based DWDM pluggable optics, the ADVA DCI OLS now features components specifically engineered to meet 400ZR DCI demands. The latest trials using a 120km single-mode fiber show that it exceeds 400ZR performance requirements under fully loaded conditions including 75GHz channel spacing, enabling an aggregate capacity of 26Tbit/s per fiber. ADVA’s DCI OLS and Acacia and Inphi’s QSFP-DD 400ZR modules offer operators a complete and validated solution built on best-of-breed components.
“Acacia has a long, proven history of pluggable silicon photonics innovation and has continually driven down the level of power consumption, size and cost of coherent interconnects,” said Tom Williams, VP, marketing, Acacia Communications. “400Gbit/s coherent pluggables enable network operators to support their growing bandwidth demands using power-efficient solutions that offer operational flexibility. By showcasing the interoperability of our high-performance coherent platform in a QSFP form factor with ADVA’s new DCI OLS, we’re giving DCI networks a clear path to a compact and cost-efficient optical layer assembled with best-in-class innovation.”
“With the introduction of COLORZ® 100G in 2016, Inphi’s silicon photonics-based QSFP transceivers along with ADVA’s line systems created a simpler and more cost-efficient way to connect data centers. Inphi’s COLORZ® II 400ZR QSFP-DD transceiver, with its low-power coherent DSP and silicon photonics engine, takes IP over DWDM to the next level. COLORZ® II 400ZR enables large cloud operators to connect metro data centers at a fraction of the cost of traditional coherent transport systems and allows switch and router companies to offer the same density for both coherent DWDM and client optics in the same chassis. Interoperable 400ZR solutions allow customers to deploy a validated ecosystem with our innovative low-power, high-performing pluggable solutions and ADVA’s next-generation DCI OLS,” said Josef Berger, AVP, optical interconnect, Inphi. “400ZR empowers DCI operators to select best-in-class components that reduce the total cost of ownership of their cloud networks.”
More information on the demo is available in these slides: https://adva.li/acacia-inphi-demo-slides .
Watch this video for further details on the new ADVA DCI OLS: https://youtu.be/8zI3E46oMBo .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
All trademarks used herein are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005107/en/
Social Media:
https://www.facebook.com/pages/ADVA-Optical-Networking/37630238931
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom